Compound Radar

Abbott Laboratories (ABT) Stock Analysis

United States · Healthcare / Medical Devices

Price $105.52
Market cap $182.59B
Next earnings Oct 14, 2026
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

70
70/100 High Quality
  • Financial Health 65
  • Profitability 65
  • Business Quality 80
  • Balance Sheet 55
  • Cash Flow 80

Why this rating?

Health 70/100 — High Quality

Strongest Business Quality 80/100
Softest Balance Sheet 55/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Abbott Laboratories (ABT) is a Medical Devices company in the Healthcare sector. Compound Radar rates Abbott Laboratories 70/100 (High Quality) due to high business quality, steady revenue growth, and manageable leverage.

Investment profile

  • Quality High
  • Growth Moderate
  • Balance Sheet Adequate
  • Valuation Attractive

Financial highlights

Valuation

  • P/E 34.15
  • Forward P/E 17.4
  • PEG 1.99
  • EV/Revenue 4.62

Profitability

  • Revenue Growth 13.0%
  • Gross Margin 56.8%
  • Operating Margin 14.7%
  • Net Margin 11.6%
  • ROE 10.6%

Financial strength

  • Cash $5.60B
  • Debt $32.72B
  • Net Cash $-27.12B
  • Free Cash Flow $7.39B
  • Current Ratio 1.38

Similar companies

Peers in Medical Devices, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Medical Devices →

FAQ

How Compound Radar scores and tracks Abbott Laboratories (ABT).

View Methodology & FAQ →